These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 1312696)
21. Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines. Sekido Y; Bader SA; Carbone DP; Johnson BE; Minna JD Cancer Res; 1994 Sep; 54(18):4988-92. PubMed ID: 8069866 [TBL] [Abstract][Full Text] [Related]
22. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Kishimoto Y; Murakami Y; Shiraishi M; Hayashi K; Sekiya T Cancer Res; 1992 Sep; 52(17):4799-804. PubMed ID: 1324794 [TBL] [Abstract][Full Text] [Related]
23. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer. Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268 [TBL] [Abstract][Full Text] [Related]
24. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814 [TBL] [Abstract][Full Text] [Related]
25. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors. Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974 [TBL] [Abstract][Full Text] [Related]
26. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer. Oh Y; Proctor ML; Fan YH; Su LK; Hong WK; Fong KM; Sekido YS; Gazdar AF; Minna JD; Mao L Oncogene; 1998 Sep; 17(9):1141-8. PubMed ID: 9764824 [TBL] [Abstract][Full Text] [Related]
27. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Chung KY; Mukhopadhyay T; Kim J; Casson A; Ro JY; Goepfert H; Hong WK; Roth JA Cancer Res; 1993 Apr; 53(7):1676-83. PubMed ID: 8453641 [TBL] [Abstract][Full Text] [Related]
28. [Correlation between p53 gene mutation and protein expression in 30 cases of human lung cancer]. Zhang J; Zheng J; Fang W Zhonghua Yi Xue Za Zhi; 1998 Nov; 78(11):846-9. PubMed ID: 11038779 [TBL] [Abstract][Full Text] [Related]
29. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer. Wu WG; Soria JC; Wang L; Kemp BL; Mao L Anticancer Res; 2000; 20(6B):4525-9. PubMed ID: 11205299 [TBL] [Abstract][Full Text] [Related]
30. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613 [TBL] [Abstract][Full Text] [Related]
31. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Wagata T; Shibagaki I; Imamura M; Shimada Y; Toguchida J; Yandell DW; Ikenaga M; Tobe T; Ishizaki K Cancer Res; 1993 Feb; 53(4):846-50. PubMed ID: 8094033 [TBL] [Abstract][Full Text] [Related]
32. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774 [TBL] [Abstract][Full Text] [Related]
33. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Medina PP; Carretero J; Fraga MF; Esteller M; Sidransky D; Sanchez-Cespedes M Genes Chromosomes Cancer; 2004 Oct; 41(2):170-7. PubMed ID: 15287030 [TBL] [Abstract][Full Text] [Related]
34. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731 [TBL] [Abstract][Full Text] [Related]
35. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Sekido Y; Bader S; Latif F; Gnarra JR; Gazdar AF; Linehan WM; Zbar B; Lerman MI; Minna JD Oncogene; 1994 Jun; 9(6):1599-604. PubMed ID: 8183553 [TBL] [Abstract][Full Text] [Related]
36. p53 mutations in bladder carcinoma cell lines. Cooper MJ; Haluschak JJ; Johnson D; Schwartz S; Morrison LJ; Lippa M; Hatzivassiliou G; Tan J Oncol Res; 1994; 6(12):569-79. PubMed ID: 7787250 [TBL] [Abstract][Full Text] [Related]
37. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development. Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748 [TBL] [Abstract][Full Text] [Related]
38. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Lerman MI; Minna JD Cancer Res; 2000 Nov; 60(21):6116-33. PubMed ID: 11085536 [TBL] [Abstract][Full Text] [Related]
39. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Huang Y; Meltzer SJ; Yin J; Tong Y; Chang EH; Srivastava S; McDaniel T; Boynton RF; Zou ZQ Cancer Res; 1993 Apr; 53(8):1889-94. PubMed ID: 8467510 [TBL] [Abstract][Full Text] [Related]
40. Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Lohmann DR; Fesseler B; Pütz B; Reich U; Böhm J; Präuer H; Wünsch PH; Höfler H Cancer Res; 1993 Dec; 53(23):5797-801. PubMed ID: 8242638 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]